Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Cash from Investing Activities (2019 - 2025)

Historic Cash from Investing Activities for Revolution Medicines (RVMD) over the last 7 years, with Q3 2025 value amounting to $24.8 million.

  • Revolution Medicines' Cash from Investing Activities rose 21574.36% to $24.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$349.7 million, marking a year-over-year increase of 3546.2%. This contributed to the annual value of -$554.4 million for FY2024, which is 6182.06% down from last year.
  • Latest data reveals that Revolution Medicines reported Cash from Investing Activities of $24.8 million as of Q3 2025, which was up 21574.36% from $34.3 million recorded in Q2 2025.
  • Revolution Medicines' Cash from Investing Activities' 5-year high stood at $107.9 million during Q2 2024, with a 5-year trough of -$392.9 million in Q4 2024.
  • For the 5-year period, Revolution Medicines' Cash from Investing Activities averaged around -$53.7 million, with its median value being -$7.1 million (2022).
  • In the last 5 years, Revolution Medicines' Cash from Investing Activities soared by 180666.96% in 2022 and then crashed by 630535.54% in 2024.
  • Revolution Medicines' Cash from Investing Activities (Quarter) stood at $8.5 million in 2021, then plummeted by 183.25% to -$7.1 million in 2022, then crashed by 5254.76% to -$380.4 million in 2023, then decreased by 3.29% to -$392.9 million in 2024, then surged by 106.32% to $24.8 million in 2025.
  • Its last three reported values are $24.8 million in Q3 2025, $34.3 million for Q2 2025, and -$15.9 million during Q1 2025.